Dieter Kadereit

USPTO Granted Patents = 57 (Patent Applications = 7)

CIPO Patents = 12 (Patent Applications = 9)

EPO Patents = 36 (Patent Applications = 36)

Average Co-Inventor Count = 7.2

ph-index = 5

Forward Citations = 106(Granted Patents)

Forward Citations (Not Self Cited) = 83(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Idstein, DE (2006)
Kelkheim, DE (2006 - 2012)
Offenbach, DE (2008 - 2018)
Frankfurt-am-Main, DE (2012 - 2022)

Company Filing History:

Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

patents

where one patent can have more than one assignee

Years Active: 2006-2024

Loading Chart...

Areas of Expertise:

GLP-1 Agonists

Dual Agonists

Hyaluronic Acid Conjugates

GPR119 Modulators

Peptidic Compounds

Isoquinoline Derivatives

Oxazolopyrimidine Derivatives

Carboxylic Acid Derivatives

Metabolic Syndrome Treatments

Acylamino-Substituted Derivatives

Pyrrolidinone Derivatives

Peptide Analogues

57 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12109395 - Device and mixing and/or reconstitution method (2024-10-08),

2. 11504473 - Mixing and/or reconstitution system and respective method (2022-11-22),

3. 11141489 - Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid (2021-10-12),

4. 10806797 - Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate (2020-10-20),

5. 10792367 - Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid (2020-10-06),

6. 10538567 - Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists (2020-01-21),

7. 10519211 - Compounds as peptidic GLP1/glucagon/GIP receptor agonists (2019-12-31),

8. 9982029 - Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists (2018-05-29),

9. 9908868 - Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2018-03-06),

10. 9896434 - Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2018-02-20),

11. 9789165 - Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists (2017-10-17),

12. 9782411 - {4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury (2017-10-10),

13. 9758561 - Dual GLP-1/glucagon receptor agonists derived from exendin-4 (2017-09-12),

14. 9758520 - Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders (2017-09-12),

15. 9751926 - Dual GLP-1/GIP receptor agonists (2017-09-05),

Title: The Innovative Journey of Dieter Kadereit

Introduction: Dieter Kadereit, a visionary inventor hailing from Frankfurt am Main, DE, has made significant contributions to the world of technology and innovation through his groundbreaking inventions.

Latest Patents: Dieter Kadereit's latest patents focus on renewable energy solutions, with a series of inventions aimed at enhancing the efficiency of solar power systems and reducing environmental impact.

Career Highlights: With a career spanning over two decades, Dieter Kadereit has established himself as a leading figure in the field of sustainable technology. His work has been recognized globally for its ingenuity and practical applications.

Collaborations: Throughout his career, Dieter Kadereit has collaborated with top research institutions and leading companies in the renewable energy sector. His partnerships have led to the development of cutting-edge technologies that are shaping the future of clean energy.

Conclusion: Dieter Kadereit's passion for innovation and commitment to sustainability continue to drive his work forward, inspiring the next generation of inventors to create a more sustainable world.

This text is generated by artificial intelligence and may not be accurate.